###begin article-title 0
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5Delta32 Genotypes in a German HIV-1 Seroconverter Cohort and Report of HIV-1 Infection in a CCR5Delta32 Homozygous Individual
###end article-title 0
###begin p 1
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 320 325 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 376 383 <span type="species:ncbi:9606">patient</span>
###xml 702 707 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recruited patients in an HIV clinic: DO HJ NO AJ. Collected EDTA blood samples and clinical data of these patients: DO HJ NO AJ. Obtained the ethical vote for this collective: DO HJ CK NO GP BB AJ. Provided detailed clinical information on the CCR5-delta 32 homozygous individual: HJ. Provided DNA samples of the German HIV-1 Seroconverter Study patients: CK GP BB. Collected patient data: CK GP BB. Provided sequence-inferred coreceptor usage information for the CCR5-delta 32 homozygous individual: CK. Performed statistical data analysis: KN. Recruited healthy controls: AP. Designed and supervised the genotyping efforts, and wrote the manuscript: RS. Designed, supervised and conducted the German HIV-1 Seroconverter Study: OH.
###end p 1
###begin p 2
###xml 43 51 <span type="species:ncbi:9606">Children</span>
Current address: The Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States of America
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 139 142 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 202 207 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Homozygosity (Delta32/Delta32) for the 32 bp deletion in the chemokine receptor 5 (CCR5) gene is associated with strong resistance against HIV infection. Heterozygosity is associated with protection of HIV-1 disease progression.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 361 363 349 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 152 155 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 177 180 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 444 447 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 457 460 <span type="species:ncbi:9606">man</span>
We genotyped a population of 737 HIV-positive adults and 463 healthy controls for the CCR5Delta32 deletion and found heterozygous frequencies of 16.2% (HIV-negative) and 17.5% (HIV-positive) among Caucasian individuals. Analysis of CCR5Delta32 influence on disease progression showed notably lower viral setpoints and a longer time to a CD4 count of <200 microl-1 in seroconverters heterozygous for the deletion. Furthermore, we identified one HIV-positive man homozygous for the Delta32 deletion.
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 113 116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 242 245 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The protective effect of CCR5 Delta32 heterozygosity is confimed in a large cohort of German seroconverters. The HIV-infected CCR5 Delta32 homozygous individual, however, displays extremely rapid disease progression. This is the 12th case of HIV-infection in this genotype described worldwide.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 94 97 94 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-ArenzanaSeisdedos1">[1]</xref>
###xml 99 102 99 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Lederman1">[2]</xref>
###xml 344 347 336 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Huang1">[3]</xref>
###xml 348 351 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Marmor1">[6]</xref>
###xml 489 492 477 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Huang1">[3]</xref>
###xml 494 497 482 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Dean1">[7]</xref>
###xml 498 502 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Mulherin1">[11]</xref>
###xml 616 620 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Winkler1">[12]</xref>
###xml 621 625 609 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Martin1">[15]</xref>
###xml 733 736 717 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Lederman1">[2]</xref>
###xml 738 742 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-OBrien1">[16]</xref>
###xml 863 867 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Balotta1">[17]</xref>
###xml 868 872 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Iversen1">[26]</xref>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 328 333 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 438 443 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 518 523 <span type="species:ncbi:9606">human</span>
###xml 587 590 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 692 695 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 744 749 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptor-5 (CCR5) is of major importance for the transmission of HIV-1 (reviewed in [1], [2]). CCR5Delta32 is a deletion resulting in a defective phenotype of this receptor, and the first host polymorphism with an effect on HIV-1 disease demonstrated: CCR5Delta32 homozygous individuals are potently protected against HIV-1 infection [3]-[6]. CCR5Delta32 heterozygosity has been shown to be significantly associated with slower HIV-1 disease progression in several study cohorts [3], [7]-[11]. Whereas other human mutations have been demonstrated since then to also affect the HIV disease progression rate [12]-[15], CCR5Delta32 is still regarded as the strongest genetic factor of HIV resistance of the host known to date [2], [16]. HIV-1 infection in CCR5Delta32 homozygotes is exceedingly rare, with a total of eleven cases reported worldwide so far [17]-[26].
###end p 10
###begin p 11
###xml 125 128 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 215 218 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 276 279 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 451 454 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 547 550 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The objective of this study was to assess the influence of the CCR5Delta32 deletion on susceptibility to, and progression of HIV infection in a large German study population. A study group of 737 well characterized HIV-positive patients, including 499 seroconverters, and 463 HIV-negative controls, was examined for presence of the deletion allele. Our results confirm the previously conveyed CCR5Delta32 associations. Furthermore, we here report one HIV-infected male displaying homozygosity for the mutation. This individual represents the 12th HIV case with the homozygous mutant (Delta32/Delta32) genotype known in the world.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distribution of CCR5Delta32 genotypes in the study cohort and identification of an HIV-1 infected individual homozygous for the CCR5Delta32 deletion
###end title 13
###begin p 14
###xml 616 619 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 737 740 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 946 953 914 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002747-t001">Table 1</xref>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 256 268 <span type="species:ncbi:9606">participants</span>
In order to examine the association of the CCR5Delta32 deletion with HIV-1 susceptibility in a German study cohort for the first time, its presence was assessed in a total of 737 seropositive patients and 463 seronegative controls. Among the African study participants, the Delta32 variant was detected in only one control subject, who was heterozygous. In a total of 1139 Caucasians, 16.7% were CCR5Delta32 heterozygous (+/Delta32) and 0.2% were homozygous (Delta32/Delta32), and genotypes were distributed similarly between cases and controls: Among the seropositive study subjects, 83.7% displayed the common CCR5+/+ genotype, whereas 16.2% were heterozygous for the deletion allele (+/Delta32). Of the seronegative controls, the CCR5+/+ genotype was found in 82.2%, while 17.5% were heterozygous. No significant association of CCR5Delta32 state with serostatus was found, regardless of whether analysis was performed by genotype frequencies (Table 1) or by allele frequencies (data not shown).
###end p 14
###begin title 15
###xml 37 40 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCR5Delta32 genotype distribution in HIV-positive and HIV-negative study subjects
###end title 15
###begin p 16
2x2 or 3x2 chi2 comparisons, depending on the presence or absence of heterozygous and mutant homozygotes in the respective subgroup. Comparisons were conducted separately according to ethnicity
###end p 16
###begin p 17
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 208 211 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Of particular note, one (0.1%) HIV-1 infected individual was found to be homozygous for the CCR5Delta32 allele. The Delta32/Delta32 genotype is generally regarded to render almost complete resistance against HIV-infection.
###end p 17
###begin title 18
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association of CCR5Delta32 genotype with HIV-1 disease progression in Caucasian seroconverters
###end title 18
###begin p 19
###xml 311 314 307 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 384 390 380 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002747-g001">Fig. 1</xref>
###xml 609 610 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 676 682 664 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002747-g002">Fig. 2</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To evaluate the impact of CCR5Delta32 on the progression of HIV-1 disease in the study cohort, the strength of the association between heterozygosity and viral load setpoints was assessed. This revealed a trend towards decreased setpoints in heterozygous seroconverters as compared to those with the common CCR5+/+ genotype without reaching statistical signifcance, however (p = 0.1; Fig. 1). A protective effect of CCR5Delta32 heterozygosity became also apparent in Kaplan-Meier analysis of 496 therapy-naive seroconverters demonstrating that mutation carriers reached the study endpoint of <200 microl-1 CD4+ T-cells later than carriers of the common gene variant (p = 0.1; Fig. 2).
###end p 19
###begin title 20
Relation of CCR5Delta32 genotype with viral setpoints in 319 Caucasian seroconverters.
###end title 20
###begin p 21
###xml 57 77 57 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Material and Methods</xref>
Scattered dots represent individual viral setpoints (see Material and Methods for a definition), whereas vertical lines demarcate the median in each genetic group.
###end p 21
###begin title 22
###xml 97 98 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 123 125 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
Kaplan Meier Analysis of 506 seroconverters showing a relation of CCR5Delta32 genotype with a CD4+ T-cell count <200 microl-1.
###end title 22
###begin p 23
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 275 277 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
A CD4+ T-cell count <200 microl-1 was documented for n = 57 of 422 individuals homozygous for the wildtype CCR5 genotype, and for n = 9 out of 84 CCR5Delta32 heterozygotes. Data censoring was due to introduction of antiretroviral therapy before a CD4 cell count of 200 microl-1 was reached. The difference between both groups implied by the Kaplan-Meier diagram is reflected in a statistical trend (p = 0.1 as calculated by the Log-Rank test).
###end p 23
###begin title 24
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characteristics of an HIV-1 positive individual homozygous for the CCR5Delta32 deletion
###end title 24
###begin p 25
###xml 483 485 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 519 521 503 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 794 795 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 823 825 803 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 834 835 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 863 865 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 945 947 921 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1140 1141 1116 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1210 1216 1186 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002747-g003">Fig. 3</xref>
###xml 1582 1583 1558 1559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1621 1623 1593 1595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1645 1647 1613 1615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1732 1734 1700 1702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1754 1756 1722 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1897 1898 1865 1866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1951 1953 1915 1917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 2142 2143 2106 2107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2196 2198 2156 2158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 10 17 <span type="species:ncbi:9606">patient</span>
###xml 61 68 <span type="species:ncbi:9606">patient</span>
###xml 145 150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 195 200 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 297 304 <span type="species:ncbi:9606">patient</span>
###xml 730 737 <span type="species:ncbi:9606">patient</span>
###xml 1277 1284 <span type="species:ncbi:9606">patient</span>
###xml 1401 1408 <span type="species:ncbi:9606">patient</span>
###xml 1969 1976 <span type="species:ncbi:9606">patient</span>
###xml 1991 2006 <span type="species:ncbi:624">Shigella sonnei</span>
###xml 2050 2057 <span type="species:ncbi:9606">patient</span>
The HIV-1 patient tested Delta32/ Delta32 homozygous (termed patient #12 hereafter) is a German male in his early 40s whose only risk factor for HIV-1 infection is homosexual contact. Results of HIV-1 antibody / antigene tests were repeatedly negative until mid-February, 2002. In June 2002, this patient presented with weakness, a sore throat, pronounced cervical, inguinal and axillary lymphadenopathy, a truncal erythematous macular rash as well as leukopenia (nadir, 2.700 microl-1 ) and thrombocytopenia (79 microl-1). A suspect diagnosis of acute retroviral syndrome was corroborated by a positive enzyme immunoassay. Western Blot was initially negative for all bands, but turned positive for the p24 and GP160 bands on the patient's follow-up visit one week later. At this visit, his CD4+ T-cell count was 344 microl-1, his CD8+ T-cell count was 826 microl-1 and the viral RNA load in his plasma had a concentration of 2.323.000 copies ml-1. Highly active antiretroviral therapy (HAART) with efavirenz, stavudine and lopinavir-ritonavir was initiated 8 days after the first positive test result. Full suppression of viremia and a CD4+ T-cell count rise were observed until eight months after infection (Fig. 3), when treatment was suspended following the request of the patient. Clinically, apart from one episode of Chlamydia-associated proctitis successfully treated with azithromycine, this patient was doing well subsequent to HAART discontinuation. However, in the following months disease progression parameters deteriorated rapidly. Within the course of ten months CD4+ T-cells count dropped from 924 microl-1 (28.1%) to 275 microl-1 (12.9%), while plasma viral load rose from below the detection limit of 50 copies ml-1 to 22 400 copies ml-1. This prompted re-initiation of antiretroviral therapy with zidovudine plus lamivudine and efavirenz; viral load became undetectable and CD4+ T-cell counts recovered. A CD4 decline to 164 microl-1, seen when the patient suffered from Shigella sonnei gastroenteritis, was transient. As of now, patient #12 has remained on the same therapeutic regime for over four years, with stable CD4+ T-cell percentages ranging between 20 and 26% microl-1 and viral loads below the limit of detection.
###end p 25
###begin title 26
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 74 81 <span type="species:ncbi:9606">patient</span>
###xml 123 130 <span type="species:ncbi:9606">patient</span>
Clinical, immunological and viral load characteristics in an HIV-infected patient homozygous for the CCR5Delta32 deletion (patient#12).
###end title 26
###begin p 27
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 420 421 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 458 463 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 499 504 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antiretroviral therapy was initiated twice, eight days after diagnosis with efavirenz (EFV), stavudine (d4T) and lopinavir-ritonavir (LPVr) and again, following rapid disease progression, 18 months after diagnosis with Efavirenz and Zidovudine (AZT) plus Lamivudine (3TC). Unbroken line with closed circles: CD4+ T-cell counts. Unbroken line with closed diamonds: Plasma viral loads. Broken line with closed circles: CD8+ T-cell counts. Blue arrow: negative HIV-1 antibody test. Red arrow: positive HIV-1 antibody test. Black arrows: Proctitis (1) / Shigellosis (2).
###end p 27
###begin title 28
Discussion
###end title 28
###begin title 29
###xml 80 92 <span type="species:ncbi:9606">participants</span>
Distribution of CCR5Delta32 genotypes among seropositive and seronegative study participants
###end title 29
###begin p 30
###xml 276 280 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Heiken1">[21]</xref>
###xml 282 286 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Martinson1">[38]</xref>
###xml 288 292 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Hummel1">[39]</xref>
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 350 353 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Variations within the host's genome contribute substantially to the individual course of HIV-1 infection. Our results obtained from the examination of a large study collective confirm the previous findings of a high prevalence of the CCR5Delta32 allele in European Caucasians [21], [38], [39]; it may therefore significantly affect susceptibility to HIV-infection, as well as progression to AIDS in this population.
###end p 30
###begin p 31
###xml 102 105 98 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Marmor1">[6]</xref>
###xml 107 111 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Philpott1">[40]</xref>
###xml 113 117 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Pasi1">[41]</xref>
###xml 631 634 619 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-ArenzanaSeisdedos1">[1]</xref>
###xml 636 639 624 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Dean1">[7]</xref>
###xml 85 88 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 383 386 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Some studies have proposed that CCR5Delta32 heterozygotes could be protected against HIV transmission [6], [40], [41]. The seronegative controls examined here are not exposed but uninfected individuals in the strict sense. However, assuming that the resistance conferred by the +/Delta32 genotype was strong, our study would have revealed an under-representation of this genotype in HIV-infected as compared to uninfected subjects. As CCR5+/Delta32 frequencies were similar in both groups, our results are more in accordance with those described by other investigators, indicating that heterozygosity-associated protection is mild [1], [7].
###end p 31
###begin title 32
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association of CCR5Delta32 carriage with HIV-1 disease progression in Caucasian seroconverters
###end title 32
###begin p 33
###xml 359 360 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 373 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#181;l</sup>
###xml 403 406 391 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Dean1">[7]</xref>
###xml 407 411 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Mulherin1">[11]</xref>
###xml 413 417 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Pasi1">[41]</xref>
The well-established CCR5+/Delta32 related restriction against disease progression was also reflected in this survey. Seroconverters displaying the normal gene variant were compared with seroconverters displaying the deletion. The CCR5+/Delta32 genotype was related to lower setpoint viral loads, as well as slower progression to the study endpoint of 200 CD4+ cells-microl in the Kaplan-Meier analysis [7]-[11], [41].
###end p 33
###begin title 34
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of an HIV-1 positive individual homozygous for the CCR5Delta32 deletion
###end title 34
###begin p 35
###xml 507 511 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-OBrien2">[23]</xref>
###xml 513 517 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Iversen1">[26]</xref>
###xml 545 549 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Heiken1">[21]</xref>
###xml 630 634 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Balotta1">[17]</xref>
###xml 635 639 615 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Gray1">[20]</xref>
###xml 641 645 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Kuipers1">[22]</xref>
###xml 647 651 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Sheppard1">[24]</xref>
###xml 653 657 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Theodorou1">[25]</xref>
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 162 165 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 671 678 <span type="species:ncbi:9606">patient</span>
So far, only 11 CCR5Delta32 homozygous HIV-1 infected individuals with the CCR5 Delta32/Delta32 genotype have been identified amongst a total of more than 20,000 HIV-positive individuals enrolled in several globally distributed cohorts. We here report one more of these extremely uncommon cases in a German study collective, further underscoring the fact that resistance conferred by the CCR5 Delta32/Delta32 genotype is strong but not complete. Transmission via contaminated blood products in hemophiliacs [23], [26] or by heterosexual contact [21] have been reported twice and once, respectively. In the majority of these cases [17]-[20], [22], [24], [25], and also in patient #12, transmission was through homosexual contact. However, this may well be due to the fact that this risk group is overrepresented in the cohorts studied so far.
###end p 35
###begin p 36
###xml 553 557 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Kuipers1">[22]</xref>
###xml 559 563 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Iversen1">[26]</xref>
###xml 866 870 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-OBrien2">[23]</xref>
###xml 872 876 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Sheppard1">[24]</xref>
###xml 878 882 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Iversen1">[26]</xref>
###xml 884 888 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Michael1">[42]</xref>
###xml 902 906 894 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Gorry1">[19]</xref>
###xml 908 912 900 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Gray1">[20]</xref>
###xml 1094 1098 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Weiser1">[43]</xref>
###xml 1137 1141 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Schuitemaker1">[44]</xref>
###xml 1142 1146 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Kreisberg1">[46]</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 342 349 <span type="species:ncbi:9606">patient</span>
###xml 629 632 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 747 754 <span type="species:ncbi:9606">patient</span>
###xml 993 998 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Patient #12 has been under continuous observation since seroconversion and extensive clinical information is available. Under antiretroviral treatment, which was initiated twice in this individual, disease progression was satisfactorily controlled. However, a therapy-free period of 10 months revealed that the natural disease course in this patient would have been devastating. The apparently paradoxical association of the supposedly protective Delta32/Delta32 genotype with unusually rapid deterioration of immune status has been observed previously [22], [26] and implies that this genotype predisposes for rather pathogenic HIV variants; indeed, proviral DNA and viral RNA sequence analysis indicated CXCR4 tropism of the virus isolated from patient #12 (Kuecherer et al., separate manuscript in preparation). Exclusive CXCR4 tropism has been described in most [23], [24], [26], [42], but not all [19], [20] of the cases where the viral strain could be isolated. Presence of CXCR4-tropic HIV-1 strains has been associated with accelerated disease progression during antiretroviral therapy [43] as well as in natural disease studies [44]-[46].
###end p 36
###begin p 37
###xml 298 302 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Heiken1">[21]</xref>
###xml 416 420 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Heiken1">[21]</xref>
###xml 493 497 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Heiken1">[21]</xref>
###xml 499 503 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Hummel1">[39]</xref>
###xml 616 619 608 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-ArenzanaSeisdedos1">[1]</xref>
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 287 294 <span type="species:ncbi:9606">Patient</span>
###xml 313 320 <span type="species:ncbi:9606">Patient</span>
Our findings included, 17% (i.e., 2 out of 12) of the known HIV-infected CCR5 Delta32 homozygotes are of German origin and have obtained infection in Germany. A common transmission chain seems rather unlikely to us, given the different geographical residences of the patients [Hannover (Patient#5, [21]), Berlin (Patient #12, this report)], as well as the different transmission routes involved [i.e. heterosexually [21], homosexually (this report)]. Neither we nor other German investigators [21], [39] have found a higher Delta32 allele frequency than that reported for most Western and Central European countries [1]. Far from being conclusive, our results might therefore indicate an enhanced circulation of CXCR4-tropic viral strains in this geographical region. With regard to the recent introduction of CCR5 antagonists as antiretroviral agents, this would be of paramount interest to the clinician.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
Study population
###end title 39
###begin p 40
###xml 121 128 121 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002747-t002">Table 2</xref>
###xml 182 214 182 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">German HIV-1 Seroconverter Study</italic>
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 189 194 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The details of the study group, which comprised 737 HIV-1-positive adults and 463 seronegative controls, are provided in Table 2. Seropositive individuals are either enrolled in the German HIV-1 Seroconverter Study (n = 648) or were recruited prospectively in a private medical clinic (Jessen-Praxis, Berlin, Germany) (n = 89); written and informed consent has been obtained from all individuals.
###end p 40
###begin title 41
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Demographic characteristics of HIV positive and HIV negative studied subjects
###end title 41
###begin p 42
Age median (IR, interquantile range) in years.
###end p 42
###begin p 43
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Of these, n = 2 individuals were occupationally exposed to HIV; risk group is unknown for n = 14 individuals.
###end p 43
###begin p 44
###xml 4 36 4 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">German HIV-1 Seroconverter Study</italic>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Bhaskaran1">[27]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Pillay1">[29]</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Duwe1">[30]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Poggensee1">[32]</xref>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 345 350 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 385 388 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 477 482 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 551 554 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 986 991 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1029 1037 <span type="species:ncbi:9606">patients</span>
###xml 1187 1194 <span type="species:ncbi:9606">patient</span>
###xml 1253 1265 <span type="species:ncbi:9606">participants</span>
###xml 1318 1321 <span type="species:ncbi:9606">men</span>
###xml 1338 1341 <span type="species:ncbi:9606">men</span>
###xml 1375 1383 <span type="species:ncbi:9606">patients</span>
The German HIV-1 Seroconverter Study, representing the German component of the CASCADE collaboration (Concerted Action on Seroconversion to AIDS and Death in Europe) [27]-[29], is a nationwide trial initiated by the Robert Koch-Institute, Berlin, in 1997. The study cohort has been described in considerable detail elsewhere [30]-[32]. Briefly, HIV-1 patients with either a documented HIV-antibody seroconversion (maximum time interval between last negative and first positive HIV-1 antibody test: 3 years) or documented ongoing seroconversion (i.e., HIV-RNA, antigen or antibody detection with an indeterminate immunoblot followed by completion of seroconversion) were recruited by the primary care physicians or clinical centers listed at the end of the manuscript. Documentation is subject to yearly follow-up and includes demographic and clinical information as well as CD4+ T-cell values, viral loads and antiretroviral therapy status. To examine the influence of host genetics on HIV-1 infection, genomic DNA of consenting patients has been prepared from peripheral blood specimens. 648 of the DNA samples were available for CCR5Delta32 genotype assessment. The median age in this patient group was 39 years (IR, 35-43 years) and 91% of the study participants were male. The four largest transmission groups are men having sex with men (MSM, 80%), heterosexuals (12%), patients from high-prevalence countries (HPL, 3%), and i.v. drug users (IVDA, 3%).
###end p 44
###begin p 45
###xml 409 413 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Oh1">[33]</xref>
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 501 513 <span type="species:ncbi:9606">participants</span>
###xml 695 707 <span type="species:ncbi:9606">participants</span>
###xml 868 880 <span type="species:ncbi:9606">participants</span>
For the purpose of this and other studies on the influence of host genetic variation on susceptibility and progression of HIV-1 disease, we have been recruiting additional seroprevalents (i.e., the duration of infection is unknown) and seroconverters not participating in the German Seroconverter Study in a private German clinic since 2004, 89 of whom were genotyped for presence of the CCR5Delta32 deletion [33]. The median age in this collective is 37 years (IR, 33-40) and most (96%) of the study participants are European-Caucasian MSM. Demographic, laboratory and clinical data, as well as the current therapy status, are documented during the routine clinical visits (for the majority of participants, 2 - 4 times / year), and are considered retrospectively as well as prospectively. For genotyping, DNA was isolated from EDTA whole blood samples for all study participants.
###end p 45
###begin p 46
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV-negative control collective consisted of 428 anonymized seronegative Caucasian blood donors, and 35 healthy, unrelated volunteers. All investigations have been conducted according to the principles expressed in the declaration of Helsinki; written approval has been granted from the Charite-Universitatsmedizin Berlin Ethical Board for all studied subjects.
###end p 46
###begin p 47
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 425 426 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 458 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
For disease progression studies, only those CD4+ T cell and viral load values gathered before the start of any antiretroviral treatment were considered in order to preclude confounding effects. Disease outcome was defined either by viral setpoint (data available for 332 seroconverters, see Statistical Methods for definition) or, in survival analysis of 506 seroconverters, by analyzing the time from seroconversion to a CD4+ T cell count below 200 microl-1.
###end p 47
###begin title 48
CCR5Delta32 genotype assessment
###end title 48
###begin p 49
###xml 152 153 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 354 383 342 371 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTCATCATCCTCCTGACAATCG-3&#8242;</named-content>
###xml 394 422 382 410 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACCAGCCCCAAGTTGACTATC-3&#8242;</named-content>
###xml 517 521 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Kristiansen1">[34]</xref>
###xml 1193 1197 1131 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Kaur1">[35]</xref>
###xml 943 946 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 983 990 <span type="species:ncbi:9606">patient</span>
CCR5Delta32 genotyping was performed by polymerase chain reaction (PCR) and subsequent gel electrophoresis. The reaction mix of 25 microl contained MgCl2 at a concentration of 1.5 mM (Qiagen, Hilden, Germany), dNTPs at 200 microM (Rapidozym, Berlin, Germany), 0.5 U HotStar Taq DNA polymerase (Qiagen, Hilden, Germany) and 5-20 ng DNA. Primers (forward, 5'-CTTCATCATCCTCCTGACAATCG-3'; reverse, 5'-GACCAGCCCCAAGTTGACTATC-3'; TibMolbiol, Berlin, Germany) were used at 0.5 microM each and have been previously described [34]. An initial denaturation step of 95degreesC for 15 min was followed by 40 amplification cycles [94degreesC, 30 s; 58degreesC, 30 s; 72degreesC, 45 s] and final extension at 72degreesC for 2 min. PCR amplicons of either 262 bp (CCR5Delta32 wildtype) or 230 bp length (CCR5Delta32 deletion) were visualized in a 3% ethidium bromide-stained agarose gel. Heterozygous samples yielded both a 262 bp and a 230 bp band. For the HIV-infected Delta32/Delta32 homozygous patient, presence of the deletion was verified by molecular sequencing and by testing DNA from a second blood sample collected on a separate occasion; furthermore, confirmatory PCR using a different primer set [35] was performed under the reaction conditions described above. Homozygous wildtype, homozygous mutant, and negative control samples were included in each reaction.
###end p 49
###begin title 50
Statistical methods
###end title 50
###begin p 51
###xml 348 352 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Speelmon1">[36]</xref>
###xml 354 358 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002747-Patke1">[37]</xref>
###xml 644 645 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 681 663 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
CCR5Delta32 genotype frequencies between seropositive and seronegative individuals were compared using the chi2 test; if expected frequencies were below 5, the exact version of the chi2 test was applied. Viral setpoints were defined as the median log10-transformed copies of viral RNA measured in plasma between 100 days and 2 years post infection [36], [37]. The strength of the association between CCR5Delta32 presence and disease severity was tested by comparison of the individual viral setpoints using the nonparametric Mann-Whitney test. For survival analysis, the Kaplan Meier method was applied, with the study endpoint defined as a CD4+ T-cell count of <200 cells microl-1. Differences between genotypes were tested by the log-rank test. We used SPSS14.01 for data management and statistical analyses, and PRISM 4 for figures.
###end p 51
###begin p 52
###xml 30 38 <span type="species:ncbi:9606">patients</span>
We are deeply indebted to the patients, their families and the clinicians who made these investigations possible. We thank Franzi Creutzburg and Diana Woellner, Charite, Berlin, for excellent technical assistance; and we are grateful to Sabrina Neumann and Hanno von Spreckelsen for skillfull technical assistance in preparation and asservation of DNA samples of seroconverters (German Seroconverter Study). Carmen Zedlack (Praxisgemeinschaft Jessen, Berlin), Christian Kollan and Parvin Ghassim (Robert Koch-Institut, Berlin) provided invaluable data management support.
###end p 52
###begin p 53
PARTICIPATING COLLABORATORS
###end p 53
###begin p 54
Aachen: Dres. Habets and Knechten; Augsburg: Dr. Hammond (Klinikum Augsburg); Berlin: Dres. Mayr, Schmidt, Speidel, and Strohbach (Medizinisches Versorgungszentrum, Arzteforum Seestrasse), PD Dr. Arasteh (Auguste-Viktoria-Krankenhaus/Vivantes), Dres. Bieniek and Cordes, Dr. Claus, Dres. Baumgarten, Carganico, and Dupke, Dres. Freiwald and Rausch, Dres. Golz, Klausen, Moll, and Schleehauf, Dr. Hintsche, Dres. Jessen and Jessen, Dres. Koppe and Krauthausen, Dr. Reuter; Bielefeld: Dr. Pfaff (Krankenhaus MARA II); Bochum: Prof. Dr. Brockmeyer (St. Joseph-Hospital); Bonn: Prof. Dr. Rockstroh (Universitatsklinik Bonn); Dortmund: Prof. Dr. Gehring and Dr. Schmaloer (Klinikum Dortmund, ID-Ambulanz); Dresden: Dr. Sawatzki (Stadtisches Krankenhaus Dresden-Neus); Duisburg: Dr. Becker-Boost, Dr. Kwirant; Dusseldorf: Prof. Dr. Haussinger and Dr. Oette (Universitatsklinik Dusseldorf); Frankfurt/Main: Prof. Dr. Helm (Universitatsklinik Johann-Wolfgang-Goethe-Universitat); Frankfurt/Oder: Dr. Markus; Halle/Saale: Dr. Kreft (Universitatsklinik Martin-Luther-Universitat); Hamburg: Prof. Dr. Plettenberg, Dr. Stoehr, Dr. Graefe, and Dr. Lorenzen (ifi, Allgemeines Krankenhaus St. Georg), Prof. Dr. Burchard, Dr. Lippert, and Dr. Manegold (Bernhard-Nocht-Institut); Dres. Adam, Schewe, and Weitner, Dr. Fenske, Dr. Gellermann, Prof. Dr. Stellbrink (Universitatsklinik Eppendorf); Hannover: Prof. Dr. Schmidt (Medizinische Hochschule Hannover), Dres. Buck and Leugner; Koblenz: Prof. Dr. Eisenhauer and Dr. Rieke (Krankenhaus Kemperhof); Koln: Dr. Bihari, Dr. Ferdinand, Prof. Dr. Fatkenheuer (Universitatsklinik Koln); Leipzig: Dr. Pfeil (Universitatsklinik Leipzig); Magdeburg: Prof. Dr. Malfertheiner and Dr. Wolle (Universitatsklinik Otto-v.-Guericke-Universitat); Mainz: Prof. Dr. Galle (Klinikum der Joh.-Gutenberg-Universitat); Munchen: Dres. Jager and Jagel-Guedes, Dr. Malm, Dr. Rieger, Stadtisches Krankenhaus Munchen-Schwabing, Prof. Dr. Froschl (Technische Universitat Munchen); Munster: Prof. Dr. Rahn, (Universitatsklinik Munster); Norderstedt: Dr. Soldan; Nurnberg: Dr. Brockhaus (Klinikum Nurnberg); Osnabruck: Dr. Mutz (Stadtische Klinik Natruper Holz); Regensburg: Prof. Dr. Salzberger, Prof. Dr. Scholmerich, and Dr. Schneidewind (Universitatsklinik Regensburg); Remscheid: Dr. Steege; Rostock: Dr. Kreft, Prof. Dr. Ziegler and Prof. Dr. Reisinger (Universitatsklinik Rostock); Stuttgart: Dres. Issler, Schaffert, Schnaitmann, and Trein, Dres. Frietsch, Muller, and Ulmer; Dr. Wagner-Wiening (Landesgesundheitsamt Stuttgart); Ulm: Prof. Dr. Kern and Prof. Dr. Dr. Kreidler (Universitatsklinik Ulm); Viernheim: Dr. van Treek; Wiesbaden: Dr. Starke.
###end p 54
###begin title 55
References
###end title 55
###begin article-title 56
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands.
###end article-title 56
###begin article-title 57
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Biology of CCR5 and its role in HIV infection and treatment.
###end article-title 57
###begin article-title 58
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
###end article-title 58
###begin article-title 59
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
###end article-title 59
###begin article-title 60
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
###end article-title 60
###begin article-title 61
###xml 85 88 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.
###end article-title 61
###begin article-title 62
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
###end article-title 62
###begin article-title 63
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.
###end article-title 63
###begin article-title 64
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 51 56 <span type="species:ncbi:9606">child</span>
###xml 97 105 <span type="species:ncbi:9606">children</span>
###xml 124 127 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group.
###end article-title 64
###begin article-title 65
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 98 106 <span type="species:ncbi:9606">children</span>
Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis.
###end article-title 65
###begin article-title 66
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
###end article-title 66
###begin article-title 67
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC).
###end article-title 67
###begin article-title 68
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
###end article-title 68
###begin article-title 69
###xml 35 38 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Advantage of rare HLA supertype in HIV disease progression.
###end article-title 69
###begin article-title 70
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.
###end article-title 70
###begin article-title 71
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genes that limit AIDS.
###end article-title 71
###begin article-title 72
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 87 94 <span type="species:ncbi:9606">patient</span>
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection in an individual homozygous for the CCR5 deletion allele.
###end article-title 73
###begin article-title 74
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele.
###end article-title 74
###begin article-title 75
###xml 40 75 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.
###end article-title 75
###begin article-title 76
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 34 37 <span type="species:ncbi:9606">man</span>
HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32.
###end article-title 76
###begin article-title 77
###xml 3 8 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A allele.
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 21 24 <span type="species:ncbi:9606">man</span>
HIV-1 infection in a man homozygous for CCR5 delta 32.
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group.
###end article-title 80
###begin article-title 81
###xml 69 97 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus.
###end article-title 81
###begin article-title 82
###xml 65 68 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors.
###end article-title 82
###begin article-title 83
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.
###end article-title 83
###begin article-title 84
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.
###end article-title 84
###begin article-title 85
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.
###end article-title 85
###begin article-title 86
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment.
###end article-title 86
###begin article-title 87
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 120 125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study.
###end article-title 87
###begin article-title 88
###xml 85 88 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A Frequent Functional Toll-like Receptor 8 Variant is Associated with Restriction of HIV Disease Progression.
###end article-title 88
###begin article-title 89
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression.
###end article-title 89
###begin article-title 90
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians.
###end article-title 90
###begin article-title 91
###xml 72 107 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
###end article-title 91
###begin article-title 92
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point.
###end article-title 92
###begin article-title 93
Global distribution of the CCR5 gene 32-basepair deletion.
###end article-title 93
###begin article-title 94
Prevalence of CCR5Delta32 polymorphism in long-term survivors of heart transplantation.
###end article-title 94
###begin article-title 95
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 genotype and resistance to vertical transmission of HIV-1.
###end article-title 95
###begin article-title 96
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.
###end article-title 96
###begin article-title 97
###xml 62 97 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
###end article-title 98
###begin article-title 99
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
###end article-title 99
###begin article-title 100
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.
###end article-title 100
###begin article-title 101
###xml 17 52 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.
###end article-title 101
###begin p 102
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 102
###begin p 103
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: D.-Y. O. is a recipient of a Rahel Hirsch Grant of the Charite-Universitatsmedizin Berlin. R.R.S. was supported by grants obtained from the Deutsche Forschungsgemeinschaft (DFG).
###end p 103

